USRE39383E1 - Process for 6-O-alkylation of erythromycin derivatives - Google Patents

Process for 6-O-alkylation of erythromycin derivatives Download PDF

Info

Publication number
USRE39383E1
USRE39383E1 US10/806,089 US80608904A USRE39383E US RE39383 E1 USRE39383 E1 US RE39383E1 US 80608904 A US80608904 A US 80608904A US RE39383 E USRE39383 E US RE39383E
Authority
US
United States
Prior art keywords
group
loweralkyl
atoms
erythromycin
oxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/806,089
Inventor
Jih-Hua Liu
George A. Foster, Jr.
Stephen H. Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US10/806,089 priority Critical patent/USRE39383E1/en
Application granted granted Critical
Publication of USRE39383E1 publication Critical patent/USRE39383E1/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for the preparation of 6-O-alkyl derivatives of erythromycin A and B which have use as intermediates for the synthesis of antibacterial agents.
  • 6-O-methylerythromycin A i.e., clarithromycin
  • This procedure is especially useful when a mixture of hydroxy-protected erythromycin derivatives (and especially those protected with silyl compounds, e.g., trimethylsilyl) is to be methylated.
  • Such mixtures of hydroxy-protected erythromycin derivatives i.e., mixtures of the 2′-mono-, 4 ⁇ -mono, and 2′,4 ⁇ -bis-protected derivatives
  • the ability to perform the alkylation on a mixture of hydroxy-protected compounds is also a distinct advantage, as costly separation steps may be avoided.
  • the invention comprises a procedure for preparing 6-O-alkyl erythromycin compounds having the formula (I): wherein:
  • Z is hydrogen, hydroxy or protected-hydroxy; by reaction of a compound of having the formula wherein R 2 , R 3 , Y mud Z are as defined above, with an alkylating reagent, as defined below, in the presence of a strong alkali metal base, as defined below, and also in the presence of a weak organic amino base, as defined below, in a stirred or agitated polar aprotic solvent, as defined below, or a mixture of such polar aprotic solvents maintained at a reaction temperature and for a period of time sufficient to effect alkyation.
  • the compounds produced by the process of the invention are subsequently deprotected at the 2′ (R 2 ) and 4 ⁇ (R 3 ) positions to give the commercially desired 60-alkyl antibacterial agents.
  • Embodiment A of the invention is the procedure for preparing 6-O-alkyl erythromycin compounds having the formula (I): wherein:
  • Y is selected from the group consisting of
  • Z is hydrogen, hydroxy or protected-hydroxy; by reaction of a compound having the formula: wherein R 3 , R 3 , Y and Z are as defined above, with an alkylating reagent, typically comprising methyl bromide, ethyl bromide, n-propyl bromide, methyl iodide, ethyl iodide, n-propyl bromide, dimethyl sulfate, diethyl sulfate, di-n-propyl sulfate, methyl-p-toluenesulfonate, ethyl methanesulfonate, and n-propyl methanesulfonate, in the presence of a strong alkali metal base, preferably selected from the group consisting of an alkali metal hydride, alkali metal hydroxide or alkali metal alkoxide, and also in the presence of a weak organic amino base, preferably selected from the group consisting of
  • Embodiment B is that procedure of Embodiment A, wherein R 2 and R 3 independently are hydrogen or a substituted silyl group of formula SiR 8 R 9 R 10 wherein R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, a loweralkyl) group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms; with the requirements that at least one of R 8 , R 9 and R 10 is not a hydrogen atom and that R 2 and R 3 may not both be hydrogen simultaneously.
  • Embodiment C is that procedure of Embodiment A, wherein Y is an oxime having the formula wherein
  • Embodiment D is that procedure of Embodiment A, wherein Z is hydroxy.
  • Embodiment E is that procedure of Embodiment A, wherein the alkylating reagent is selected from the group consisting of methyl bromide, methyl iodide, dimethyl sulfate and methyl-p-toluenesulfonate.
  • Embodiment F is that procedure of Embodiment A, wherein the reaction is maintained at a temperature from ⁇ 5° C. to +5° C.
  • Embodiment G is that procedure of Embodiment A, wherein the solvent is a minute of solvents consisting of N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile and ethyl acetate,
  • Embodiment H is that procedure of Embodiment A, wherein the strong alkali metal base is an alkali metal hydroxide
  • Embodiment I is that procedure of Embodiment A, wherein the weak organic amine base is selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine and 1-ethylpiperidine.
  • the weak organic amine base is selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine and 1-ethylpiperidine.
  • Embodiment J is that procedure of Embodiment A, wherein R 2 and R 3 an independently selected from hydrogen or a substituted silyl group of formula SiR 8 R 9 R 10 , wherein R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, s phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms and with the requirements that at least one of R 8 R 9 and R 10 is not a hydrogen atom and that both R 2 and R 3 may not be hydrogen; Y is an oxime having the formula wherein
  • Embodiment K is that procedure of Embodiment A, wherein R 2 and R 3 are independently hydrogen or a trimethylsilyl group but R 2 and R 3 may not both be hydrogen simultaneously; Y is a isopropyl cyclohexyl ketal oxime group; Z is hydroxy; the alkylating reagent consists of methyl bromide, methyl iodide, dimethyl sulfate, or methyl-p-toluenesulfonate; the strong alkali metal base is potassium hydroxide; the weak organic amine base is triethylamine; the solvent is a mixture of THF and DMSO; and the reaction is maintained at a temperature from ⁇ 5° C. to 0° C.
  • novel intermediate compounds 4′′-TMS-erythromycin A oxime IPCH ketal and 2′-TMS-erythromycin A oxime IPCH ketal.
  • alkyl refers to saturated, straight- or branched-chain hydrocarbon radicals containing between one and ten carbon atoms including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl and neopentyl.
  • alkylating reagent refers to a reagent capable of placing an alkyl group onto a nucleophilic site, including, but not limited to, alkyl halides such as methyl bromide, ethyl bromide, n-propyl bromide, methyl iodide, ethyl iodide, n-propyl bromide; dialkyl sulfates such as dimethyl sulfate, diethyl sulfate, di-n-propyl sulfate; and alkyl or aryl sulfonates such as methyl-p-toluenesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, and the like.
  • alkyl halides such as methyl bromide, ethyl bromide, n-propyl bromide, methyl iodide, ethy
  • aryl(loweralkyl) refers to a loweralkyl radical having appended thereto 1-3 aromatic hydrocarbon groups, as for example benzyl, diphenylbenzyl, trityl and phenylethyl.
  • aryloxy refers to an aromatic hydrocarbon radical which is joined to the rest of the molecule via an ether linkage (i.e., through an oxygen atom), as for example phenoxy.
  • cycloalkyl refers to a saturated monocyclic hydrocarbon radical having from three to eight carbon atoms in the ring and optionally substituted with between one and three additional radicals selected from among loweralkyl, halo(loweralkyl), loweralkoxy, halogen.
  • cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-fluoro-cyclopropyl, 2-fluorocyclopropyl and 2-aminocyclopropyl.
  • hydroxy-protecting group is well-known in the art and refers to substituents on functional hydroxy groups of compounds undergoing chemical transformation which prevent undesired reactions and degradations during a synthesis (see, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991)).
  • hydroxy-protecting groups include, but are not limited to, benzyloxycarbonyl, acetyl, or a substituted silyl group of formula SiR 8 R 9 R 10 , wherein R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms and wherein at heat one of R 8 , R 9 and R 10 is not a hydrogen atom; and the like
  • loweralkenyl refers to a straight-or branched-chain hydrocarbon radical containing between two and six carbon atoms and possessing at least are carbon-carbon double bond.
  • Examples of loweralkenyl radicals include vinyl, allyl, 2- or 3-butenyl, 2-,3- or 4-pentenyl, 2-,3-,4- or 5-hexenyl and isomeric forms thereof.
  • loweralkoxy refers to an loweralkyl radical which is joined to the rest of the molecule via an ether linkage (i.e., through in oxygen atom).
  • loweralkoxy radicals include, but are not limited to, methoxy and ethyloxy.
  • loweralkyl refers to an alkyl radical containing one to six carbon atoms including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl and neopentyl.
  • protected hydroxy refers to a hydroxy group protected with a hydroxy protecting group, as defined above.
  • polar aprotic solvent refers to polar organic solvents lacking an easily removed proton , including, but not limited to N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile or ethyl acetate, and the like.
  • strong alkai metal base refers to an alkali metal horse having a weak conjugate acid, including, but not limited to, sodium hydroxide, postassium hydroxide, sodium hydride, potassium hydride, potassium t-butoxide, and the like.
  • substituted aryl(loweralkyl) refers to an aryl (loweralkyl) residue as defined above having between one and that non-hydrogen ring substituents each independently selected from among halogen, loweralkoxy, loweralkyl, hydroxy-substituted loweralkyl, and (loweralkyl)amino.
  • substituted aryl (loweralkyl) radicals include 2-fluorophenylmethyl, 4-fluorophenylethyl and 2,4-difluorophenylpropyl
  • weak organic amine base refers to as organic amine base having a strong conjugate acid, including, but not limited to trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine, and 1-ethylpiperidine, and the like.
  • DMSO dimethyl sulfoxide
  • HPLC high performance liquid chromatography
  • IPCH ketal for isopropyl cyclohexyl ketal
  • TEA for triethylamine
  • THF for tetrahydrofuran
  • TMS trimethylsilyl
  • 4′′-TMS-erythromycin A oxime IPCH ketal was prepared by treating 2′,4′′-bisTMS-erythromycin A oxime IPCH ketal with acetic acid in a mixture of THF, DMSO and isopropyl alcohol at room temperature for 2 hours and 20 minutes, then diluting the mixture with isopropyl acetate and quenching with excess 2N NaOH. The organic layer was separated and dried, and the solvent was removed under vacuum to afford the 4′′-TMS-erythromycin A oxime IPCH ketal.
  • 1 H NMR assignments for the desosamine portion of the molecule are: 1′, 4.57; 2′, 3.20; 3′, 2.44, 4′, 1.69 & 1.21; 5′, 3.45; 6′, 1.21; OTMS (9H), 0.12.
  • the integral of the TMS signal (9H) indicates that a single TMS group is present in the molecule.
  • An NOE in the ROESY spectrum between the TMS group at 0.12 ppm and H2′at 3.20 ppm indicates that the TNS group is at the 2′position.
  • 2′-TMS-erythromycin A oxime IPCH ketal 2′-TMS-erythromycin A oxime IPCH ketal was prepared by treating 2′,4′′-bisTMS-erythromycin A oxime IPCH ketal with 0.5N NaOH and TEA in 1:1 THF:DMSO for 2.5 hours at room temperature. The reaction was quenched with heptane and 2N NaOH, and the layers were separated. The organic layer was washed with water and dried over MgSO4, then the solvent was removed under vacuum with additional flushing of the heptane with nitrogen to afford the 2′-TMS-erythromycin A oxime IPCH ketal. The structure was confirmed by NMR.
  • 1 H NMR assignments for the cladinose portion of the molecule are: 1′′, 4.90; 2′′, 2.36 & 1.50; 3′′-methyl, 1.14; 4′′, 3.16; 5′′, 4.24; 6′′, 1.22; Omethyl, 3.29; OTMS (9H), 0.14.
  • the integral of the TMS signal (9H) indicates that a single TMS group is present in the molecule.
  • An NOE in the ROESY spectrum between the TMS group at 0.14 ppm and H4′′at 3.16 ppm indicates that the TMS group is at the 4′′position.
  • the starting material is dissolved in the appropriate solvent and analyzed by HPLC, thus providing an exact estimate of each individual compound.
  • HPLC analysis was performed on the mixtures of products, to provide an exact estimate of each product compound.
  • Example 1 The procedure of Example 1 was followed, except TEA (1.0 g, 10 mmole) was added prior to the addition of the methyl iodide and KOH. A crude product (4.14 g) was obtained which contained 3.4 g of the 6-O-methyl products (81% yield). See Table 1 below for a summary of Examples 1,2 and 3.
  • Example 1 The procedure of Example 1 was followed, except TEA (3.5 g, 34.6 mmole) was added prior to the addition of the methyl iodide and KOH. A crude product (3.84 g) was obtained which contained 3.5 g of the 6-O-methyl products (83%). See Table 1 below for a summary of Examples 1, 2 and 3.
  • Example 4 The procedure of Example 4 was followed, except that the order of addition of reagents to the solution of starting materials was TEA (1.0 g, 10.0 mmol), methyl bromide, then KOH, to afford 3.93 g of a mixture of desired products, 6-O-methyl-2′,4′′-TMS-erythromycin A oxime IPCH ketal and 6-O-methyl-4′′-TMS-erythromycin A oxime IPCH ketal (2.58 and 0.44 mmol, respectively; overall yield 74%).
  • TEA 1.0 g, 10.0 mmol
  • methyl bromide methyl bromide
  • KOH KOH
  • Example 4 The procedure of Example 4 was followed, except that the order of addition of reagents to the solution of starting materials was TEA (3.5 g, 34.6 mmol), methyl bromide, then KOH, to afford 3.87 g of a mixture of desired products, 6-O-methyl-2′,4′′-bisTMS-erythromycin A oxime IPCH ketal and 6-O-methyl-bisTMS-erythromycin A oxime IPCH ketal (2.48 and 0.72 mmol, respectively; overall yield 79%). A trace amount of the quaternary by-product was obtained. See Table 2 below for a summary of Examples 4, 5 and 6
  • Example 7 The procedure of Example 7 was followed, except that the order of addition of reagents to the solution of starting material was TEA (3.5 g. 34.6 mmol), methyl bromide (0.5 mL, 9 mmol), then KOH (0.26 g, 3.9 mmol), to afford 1.32 g of the desired product, 6-O-methyl-4′′-TMS-erythromycin A oxime IPCH keel (68% yield), and 0.32 g of the quaternary by-product. See Table 3 below for a summary of Examples 7 and 8.
  • Example 9 The procedure of Example 9 was followed, except that the order of addition of reagents to the solution of starting material was TEA (1.75 g, 17.3 mmol), methyl bromide (0.5 mL, 9.0 mmol), then KOH (0.23 g, 3.0 mmol), to afford 1.84 g of the desired product, 6-O-methyl-2′-TMS-erythromycin A oxime IPCH ketal (74.5% yield), and 0.1 g of the quaternary by-product. See Table 4 below for a summary of Examples 9 and 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A procedure for preparing 6-O-alkyl erythromycin compounds having the formula:
Figure USRE039383-20061107-C00001
wherein R1 is a loweralkyl group, R2 and R3 an independently hydrogen or a hydroxy-protecting group, except that R2 and R3 may not both be hydrogen simultaneously; Y is oxygen or a specifically substituted oxime; and Z is hydrogen, hydroxy or protected-hydroxy; by reaction of the compound wherein R1 is hydrogen with an alkylating reagent, is the presence of a strong alkali metal base and also in the presence of a weak organic amino base, in a suitable stirred or agitated polar aprotic solvent, or a mixture of such polar aprotic solvents maintained at a reaction temperature and for a period of time sufficient to effect alkyation.

Description

FIELD OF THE INVENTION
The present invention relates to a process for the preparation of 6-O-alkyl derivatives of erythromycin A and B which have use as intermediates for the synthesis of antibacterial agents. Of particular interest is use of the invention to prepare 6-O-methylerythromycin A (i.e., clarithromycin) in higher yields.
BACKGROUND
The 6-O-methylation of various erythromycin derivatives has been reported in several patents or published applications. U.S. Pat. No. 4,496,717 (issued Jan. 25, 1985) describes the methylation of a 2′-O-,1′-N-dibenzyloxycarbonyl derivative of erythromycin by reaction with a methylating reagent in the presence of a base such as in alkali metal hydride or an alkali metal amide. U.S. Pat. No. 4,670,549 (issued Jan. 2, 1997) describes the reaction of a quaternary salt of an erythromycin A 9-oxime with a methylating reagent in the presence of a bass such as an alkali metal hydride, hydroxide or alkoxide. U.S. Pat. No. 4,672,109 (issued Jun. 9,1987) describes the reaction of an erythromycin A 9-oxime with a methylating reagent in the presence of a bass such as an alkali metal hydride or hydroxide. European Application EP 260938 (published Mar. 23, 1988) describes 6-O-methylerythromycin derivatives prepared by the reaction of 2′-silylated erythromycin A 9-oximes with a methylating reagent in the presence of a base, such as an alkali, metal hydride, hydroxide or alkoxide, that is said to prevent undesirable quaternary salt formation. U.S. Pat. No. 4,990,602 (issued Feb. 5, 1991) describes additional 6-O-methylerythromcyin erythromycin A derivatives (more broadly substituted at the oxime position than those of EP 260938) prepared by the reaction of such 2′-silylated erythromycin, 9-oxime derivatives with a methylating reagent in the presence of a base such as an alkali metal hydride, hydroxide or alkoxide, also with the stated intention of preventing undesirable quaternary salt formation. While the U.S. Pat. No. 4,990,602 and the EP 260938 application point out the desirability of preventing quaternary salt formation, there remains a need for alternative methods for improving yields.
The continued appearance of new patents directed to 6-O-methyl erythromycin compounds is in indication of the importance of and the continuing efforts towards preventing unwanted side-reactions and to increasing the yield of the desired antibiotic compounds (e.g., clarithromycin).
In general, the process for making clarithromycin can be thought of as a four-step procedure beginning with erythromycin A as the starting material:
    • Step 1: optionally protect the 9-oxo group with an oxime;
    • Step 2: protect the 2′and 4″hydroxyl groups;
    • Step 3: methylate the 6-hydroxyl group;
    • Step 4: deprotect at the 2′, 4′and 9-positions.
We have now found that higher yields of 6-O-alkyl erythromycin derivatives may be obtained and by-product compounds reduced by means of a 6-O-alkylation procedure that utilizes a weak organic base in the presence of a strong base. This alkyation step corresponds to the general Step 3 referred to above.
This procedure is especially useful when a mixture of hydroxy-protected erythromycin derivatives (and especially those protected with silyl compounds, e.g., trimethylsilyl) is to be methylated. Such mixtures of hydroxy-protected erythromycin derivatives (i.e., mixtures of the 2′-mono-, 4Δ-mono, and 2′,4Δ-bis-protected derivatives) may be produced during large scale preparations (i.e., in Step 2 referred to above) if the bis-protection is not fully achieved. The ability to perform the alkylation on a mixture of hydroxy-protected compounds is also a distinct advantage, as costly separation steps may be avoided.
SUMMARY OF THE INVENTION
The invention comprises a procedure for preparing 6-O-alkyl erythromycin compounds having the formula (I):
Figure USRE039383-20061107-C00002
wherein:
    • R1 is a loweralkyl group, as defined below;
    • R2 and R3 are independently hydrogen or a hydroxy-protecting group, as defined below, except that R2 and R3 may not both be hydrogen simultaneously;
    • Y is selected from the group consisting of:
      • a) oxygen,
      • b) an oxime having the formula N-O-R4, wherein
    • R4 is selected from the group consisting of hydrogen,
        • a loweralkenyl group, as defined below,
        • an aryl(loweralkyl) group, as defined below, or
        • a substituted aryl(loweralkyl) group, as defined below; or
      • c) an oxime having the formula
        Figure USRE039383-20061107-C00003
        wherein
    • R5 is selected from the group consisting of:
      • a loweralkyl group,
      • a cycloalkyl group, as defined below,
      • a phenyl group,
      • an aryl(loweralkyl) group;
      • or R5 and R6 or R5 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
    • R6 is selected from the group consisting of
      • a loweralkyl group,
      • a loweralkoxymethyl group, as defined below;
      • or R6 and R5 and the atoms to which they are attached are taken together from a 5- to 7-membered ring containing one oxygen atom,
      • or R6 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group; and
    • R7 is selected from the group consisting of
      • a hydrogen atom,
      • a loweralkyl group,
      • a phenyl group,
      • an aryl(loweralkyl) group;
      • or R7 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
      • or R1 and R6 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group;
    • with the requirement that only one pair of substituents (R1 and R6), (R5 and R7) or (R6 and R7) may be taken together with the atoms to which they are attached to form a ring as defined above;
      and
Z is hydrogen, hydroxy or protected-hydroxy; by reaction of a compound of having the formula
Figure USRE039383-20061107-C00004
wherein R2, R3, Y mud Z are as defined above, with an alkylating reagent, as defined below, in the presence of a strong alkali metal base, as defined below, and also in the presence of a weak organic amino base, as defined below, in a stirred or agitated polar aprotic solvent, as defined below, or a mixture of such polar aprotic solvents maintained at a reaction temperature and for a period of time sufficient to effect alkyation.
The compounds produced by the process of the invention are subsequently deprotected at the 2′ (R2) and 4Δ (R3) positions to give the commercially desired 60-alkyl antibacterial agents.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment (Embodiment A) of the invention is the procedure for preparing 6-O-alkyl erythromycin compounds having the formula (I):
Figure USRE039383-20061107-C00005
wherein:
    • R1 is a loweralkyl group;
    • R2 and R3 are independently hydrogen or a hydroxy-protecting group, which is benzyloxycarbonyl, acetyl, or a substituted silyl group of formula SiR8R9R10, wherein R8, R9 and R10are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms; with the requirements that at least one of R8, R9 and R10 is not a hydrogen atom and that R2 and R3 may not both be hydrogen simultaneously;
Y is selected from the group consisting of
    • a) oxygen,
    • b) an oxime having the formula N-O-R4, wherein
      • R4 is selected from the group consisting of:
        • hydrogen,
        • a loweralkenyl group,
        • an aryl(loweralkyl) group, or
        • a substituted aryl(loweralkyl) group; or
      • c) an oxime having the formula
        Figure USRE039383-20061107-C00006
        wherein
    • R5 is selected from the group consisting of:
      • a loweralkyl group,
      • a cycloalkyl group,
      • a phenyl group,
      • an aryl(loweralkyl) group; or
      • R5 and R6 or R5 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
    • R6 is selected from the group consisting of:
      • a loweralkyl group,
      • a loweralkoxymethyl group;
      • or R6 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing out oxygen atom,
      • or R6 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group; and
    • R7 is selected from the group consisting of:
      • a hydrogen atom,
      • a lower alkyl group,
      • a phenyl group,
      • an aryl(loweralkyl) group,
      • or R7 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
      • or R7 and R6 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group;
    • with the requirement that only pair of substituents (R5 and R6), (R5 and R7 or R6 and R7) may be taken together with the atoms to which they are attached form to a ring as defined above;
      and
Z is hydrogen, hydroxy or protected-hydroxy; by reaction of a compound having the formula:
Figure USRE039383-20061107-C00007
wherein R3, R3, Y and Z are as defined above, with an alkylating reagent, typically comprising methyl bromide, ethyl bromide, n-propyl bromide, methyl iodide, ethyl iodide, n-propyl bromide, dimethyl sulfate, diethyl sulfate, di-n-propyl sulfate, methyl-p-toluenesulfonate, ethyl methanesulfonate, and n-propyl methanesulfonate, in the presence of a strong alkali metal base, preferably selected from the group consisting of an alkali metal hydride, alkali metal hydroxide or alkali metal alkoxide, and also in the presence of a weak organic amino base, preferably selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine, and 1-ethylpiperidine, in a suitable stirred or agitated polar aprotic solvent, selected, for example, from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile or ethyl acetate, or a mixture of such polar aprotic solvents maintained at a reaction temperature and for a period of time sufficient to effect alkyation, preferably from -15° C. to room temperature for a period of one to 8 hours.
In another embodiment of the invention (Embodiment B) is that procedure of Embodiment A, wherein R2 and R3 independently are hydrogen or a substituted silyl group of formula SiR8R9R10wherein R8, R9 and R10are the same or different and each is a hydrogen atom, a loweralkyl) group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms; with the requirements that at least one of R8, R9 and R10 is not a hydrogen atom and that R2 and R3 may not both be hydrogen simultaneously.
In another embodiment of the invention (Embodiment C) is that procedure of Embodiment A, wherein Y is an oxime having the formula
Figure USRE039383-20061107-C00008
wherein
    • R5 is selected from the group consisting of:
      • a loweralkyl group,
      • a cycloalkyl group, as defined below,
      • a phenyl group,
      • an aryl(loweralkyl) group;
      • or R5 and R6 or R-5 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
    • R6 is selected from the group consisting of
      • a loweralkyl group,
      • a loweralkoxymethyl group, as defined below;
      • or R6 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom,
      • or R6 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group; and
    • R7 is selected from the group consisting of
      • a hydrogen atom,
      • a loweralkyl group,
      • a phenyl group,
      • an aryl(loweralkyl) group;
      • or R7 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
      • or R7 and R8 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group;
    • with the requirement that only one pair of substituents (R5 and R6), (R5 and R7) or (R6 and R7) may be taken together with the atoms to which they are attached to form a ring as defined above;
In another embodiment of the invention (Embodiment D) is that procedure of Embodiment A, wherein Z is hydroxy.
In another embodiment of the invention (Embodiment E) is that procedure of Embodiment A, wherein the alkylating reagent is selected from the group consisting of methyl bromide, methyl iodide, dimethyl sulfate and methyl-p-toluenesulfonate.
In another embodiment of the invention (Embodiment F) is that procedure of Embodiment A, wherein the reaction is maintained at a temperature from −5° C. to +5° C.
In another embodiment of the invention (Embodiment G) is that procedure of Embodiment A, wherein the solvent is a minute of solvents consisting of N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile and ethyl acetate,
In another embodiment of the invention (Embodiment H is that procedure of Embodiment A, wherein the strong alkali metal base is an alkali metal hydroxide
In another embodiment of the invention (Embodiment I) is that procedure of Embodiment A, wherein the weak organic amine base is selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine and 1-ethylpiperidine.
In a preferred embodiment of the invention (Embodiment J) is that procedure of Embodiment A, wherein R2 and R3 an independently selected from hydrogen or a substituted silyl group of formula SiR8R9R10, wherein R8, R9 and R10are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, s phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms and with the requirements that at least one of R8 R9 and R10 is not a hydrogen atom and that both R2 and R3 may not be hydrogen; Y is an oxime having the formula
Figure USRE039383-20061107-C00009
wherein
    • R5 is selected from the group consisting of
      • a loweralkyl group,
      • a cycloalkyl group, as defined below,
      • a phenyl group.
      • an aryl(loweralkyl) group;
      • or R5 and R6 or R5 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
    • R6 is selected from the group consisting of:
      • a loweralkyl group,
      • a loweralkoxymethyl group, as defined below;
      • or R6 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom,
      • or R6 and R7 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group; and
    • R7 is selected from the group consisting of:
      • a hydrogen atom,
      • a loweralkyl group,
      • a phenyl group,
      • an aryl(loweralkyl) group;
      • or R7 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing an oxygen atom;
      • or R7 and R6 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group;
    • with the requirement that only pair of substituents (R5 and R6), (R5 and R7) or (R6 and R7) may be taken together with the atoms to which they are attached to form a ring as defined above;
      Z is hydroxy; the alkylating reagent is a methylating reagent consisting of methyl bromide, methyl iodide, dimethyl sulfate or methyl-p-toluenesulfonate; the strong alkali metal base is an alkali metal hydroxide; wherein the weak organic amino base is selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine, and 1-ethylpiperidine; the solvent is a mixture of solvents consisting of N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile or ethyl acetate; and the reaction is maintained at a temperature from −5° C. to 5° C.
In a more preferred embodiment of the invention (Embodiment K) is that procedure of Embodiment A, wherein R2 and R3 are independently hydrogen or a trimethylsilyl group but R2 and R3 may not both be hydrogen simultaneously; Y is a isopropyl cyclohexyl ketal oxime group; Z is hydroxy; the alkylating reagent consists of methyl bromide, methyl iodide, dimethyl sulfate, or methyl-p-toluenesulfonate; the strong alkali metal base is potassium hydroxide; the weak organic amine base is triethylamine; the solvent is a mixture of THF and DMSO; and the reaction is maintained at a temperature from −5° C. to 0° C.
In another aspect of the invention are the novel intermediate compounds, 4″-TMS-erythromycin A oxime IPCH ketal and 2′-TMS-erythromycin A oxime IPCH ketal.
DEFINITIONS
A number of defined terms are used herein to designate particular elements of the present invention. When so used, the following meanings an intended:
The term “alkyl” refers to saturated, straight- or branched-chain hydrocarbon radicals containing between one and ten carbon atoms including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl and neopentyl.
The term “alkylating reagent” refers to a reagent capable of placing an alkyl group onto a nucleophilic site, including, but not limited to, alkyl halides such as methyl bromide, ethyl bromide, n-propyl bromide, methyl iodide, ethyl iodide, n-propyl bromide; dialkyl sulfates such as dimethyl sulfate, diethyl sulfate, di-n-propyl sulfate; and alkyl or aryl sulfonates such as methyl-p-toluenesulfonate, ethyl methanesulfonate, n-propyl methanesulfonate, and the like.
The term “aryl(loweralkyl)” refers to a loweralkyl radical having appended thereto 1-3 aromatic hydrocarbon groups, as for example benzyl, diphenylbenzyl, trityl and phenylethyl.
The term “aryloxy” refers to an aromatic hydrocarbon radical which is joined to the rest of the molecule via an ether linkage (i.e., through an oxygen atom), as for example phenoxy.
The term “cycloalkyl” refers to a saturated monocyclic hydrocarbon radical having from three to eight carbon atoms in the ring and optionally substituted with between one and three additional radicals selected from among loweralkyl, halo(loweralkyl), loweralkoxy, halogen. Examples of cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-fluoro-cyclopropyl, 2-fluorocyclopropyl and 2-aminocyclopropyl.
The term “hydroxy-protecting group” is well-known in the art and refers to substituents on functional hydroxy groups of compounds undergoing chemical transformation which prevent undesired reactions and degradations during a synthesis (see, for example, T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991)). Examples of hydroxy-protecting groups include, but are not limited to, benzyloxycarbonyl, acetyl, or a substituted silyl group of formula SiR8R9R10, wherein R8, R9 and R10 are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms and wherein at heat one of R8, R9 and R10 is not a hydrogen atom; and the like
The term “loweralkenyl” refers to a straight-or branched-chain hydrocarbon radical containing between two and six carbon atoms and possessing at least are carbon-carbon double bond. Examples of loweralkenyl radicals include vinyl, allyl, 2- or 3-butenyl, 2-,3- or 4-pentenyl, 2-,3-,4- or 5-hexenyl and isomeric forms thereof.
The term “loweralkoxy” refers to an loweralkyl radical which is joined to the rest of the molecule via an ether linkage (i.e., through in oxygen atom). Examples of loweralkoxy radicals include, but are not limited to, methoxy and ethyloxy.
The term “loweralkyl” refers to an alkyl radical containing one to six carbon atoms including, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl and neopentyl.
The term “protected hydroxy” refers to a hydroxy group protected with a hydroxy protecting group, as defined above.
The term “polar aprotic solvent” refers to polar organic solvents lacking an easily removed proton , including, but not limited to N,N-dimethylformamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile or ethyl acetate, and the like.
The term “strong alkai metal base” refers to an alkali metal horse having a weak conjugate acid, including, but not limited to, sodium hydroxide, postassium hydroxide, sodium hydride, potassium hydride, potassium t-butoxide, and the like.
The term “substituted aryl(loweralkyl)” refers to an aryl (loweralkyl) residue as defined above having between one and that non-hydrogen ring substituents each independently selected from among halogen, loweralkoxy, loweralkyl, hydroxy-substituted loweralkyl, and (loweralkyl)amino. Examples of substituted aryl (loweralkyl) radicals include 2-fluorophenylmethyl, 4-fluorophenylethyl and 2,4-difluorophenylpropyl
The term “weak organic amine base” refers to as organic amine base having a strong conjugate acid, including, but not limited to trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methylpyrrolidine, 1-methylpiperidine, and 1-ethylpiperidine, and the like.
ABBREVIATIONS
Certain abbreviations are used repeatedly in the specification which follows. These include: DMSO for dimethyl sulfoxide; HPLC for high performance liquid chromatography; IPCH ketal for isopropyl cyclohexyl ketal; TEA for triethylamine; THF for tetrahydrofuran; TMS for trimethylsilyl.
STARTING MATERIALS
2′,4″-bisTMS-erythromycin A oxime IPCH ketal was prepared as described in Example 30 of U.S. Pat. No. 4,990,602.
Preparation of 4″-TMS-erythromycin A oxime IPCH ketal
4″-TMS-erythromycin A oxime IPCH ketal was prepared by treating 2′,4″-bisTMS-erythromycin A oxime IPCH ketal with acetic acid in a mixture of THF, DMSO and isopropyl alcohol at room temperature for 2 hours and 20 minutes, then diluting the mixture with isopropyl acetate and quenching with excess 2N NaOH. The organic layer was separated and dried, and the solvent was removed under vacuum to afford the 4″-TMS-erythromycin A oxime IPCH ketal. 1H NMR assignments for the desosamine portion of the molecule are: 1′, 4.57; 2′, 3.20; 3′, 2.44, 4′, 1.69 & 1.21; 5′, 3.45; 6′, 1.21; OTMS (9H), 0.12. The integral of the TMS signal (9H) indicates that a single TMS group is present in the molecule. An NOE in the ROESY spectrum between the TMS group at 0.12 ppm and H2′at 3.20 ppm indicates that the TNS group is at the 2′position.
2′-TMS-erythromycin A oxime IPCH ketal 2′-TMS-erythromycin A oxime IPCH ketal was prepared by treating 2′,4″-bisTMS-erythromycin A oxime IPCH ketal with 0.5N NaOH and TEA in 1:1 THF:DMSO for 2.5 hours at room temperature. The reaction was quenched with heptane and 2N NaOH, and the layers were separated. The organic layer was washed with water and dried over MgSO4, then the solvent was removed under vacuum with additional flushing of the heptane with nitrogen to afford the 2′-TMS-erythromycin A oxime IPCH ketal. The structure was confirmed by NMR. 1H NMR assignments for the cladinose portion of the molecule are: 1″, 4.90; 2″, 2.36 & 1.50; 3″-methyl, 1.14; 4″, 3.16; 5″, 4.24; 6″, 1.22; Omethyl, 3.29; OTMS (9H), 0.14. The integral of the TMS signal (9H) indicates that a single TMS group is present in the molecule. An NOE in the ROESY spectrum between the TMS group at 0.14 ppm and H4″at 3.16 ppm indicates that the TMS group is at the 4″position.
EXAMPLES
The following examples, which are provided for illustration and not limitation of the invention, will save to further illustrate the process and the advantages of the invention.
Where mixtures of starting material are utilized, the starting material is dissolved in the appropriate solvent and analyzed by HPLC, thus providing an exact estimate of each individual compound. A similar HPLC analysis was performed on the mixtures of products, to provide an exact estimate of each product compound.
Example 1
Methylation of 2′, 4″-bisTMS-erythromycin A oxime IPCH ketal:
Reference methylation procedure with KOH base and no TEA
A solution of 2′, 4″-bisTMS-erythromycin A oxime IPCH ketal (4.0 mmol) in 1:1 THF:DMSO (50 mL) was prepared. The solution was cooled to 0°-5° C., and methyl iodide (2.34 g, 16.5 mmol) and KOH (0:47 g. 8.3 mmol) were added in that order. The reaction mixture was stirred for 60 minutes, the reaction was diluted by addition of 100 mL of heptane, and 20 mL of 2N NaOH were added to quench the reaction. The layers were separated, and the organic layer was washed with water. The heptane layer was dried over MgSO4, and the solvent was removed under vacuum to afford 3.86 g of product containing 2.99 g of the 6-O-methyl-2′,4″-bisTMS-erythromycin A oxime IPCH ketal (71% yield). The identity of the product was confirmed by HPLC analysis and comparison with the reference product (see U.S. Pat. No. 4,990,602). See Table 1 below for a summary of Examples 1, 2 and 3.
Example 2
Methylation of 2′,4″-bisTMS-erythromycin A oxime IPCH ketal;
Methylation Procedure with KOH and Low Level of TEA
The procedure of Example 1 was was followed, except TEA (1.0 g, 10 mmole) was added prior to the addition of the methyl iodide and KOH. A crude product (4.14 g) was obtained which contained 3.4 g of the 6-O-methyl products (81% yield). See Table 1 below for a summary of Examples 1,2 and 3.
Example 3
Methylation of 2′, 4″-bisTMS-erythromycin A oxime IPCH ketal;
Methylation procedure with KOH and high level of TEA
The procedure of Example 1 was was followed, except TEA (3.5 g, 34.6 mmole) was added prior to the addition of the methyl iodide and KOH. A crude product (3.84 g) was obtained which contained 3.5 g of the 6-O-methyl products (83%). See Table 1 below for a summary of Examples 1, 2 and 3.
TABLE 1
Summary of Examples 1, 2 and 3.
starting material 6-O-methyl prod yield
Ex. No. Base (mmol) (g) (%)
1 KOH 4.0 2.99 71
2 KOH + low TEA 4.0 3.4 81
3 KOH + high TEA 4.0 3.5 83
These data demonstrate that higher yields of product are obtained in the presence of TEA and that the yield is highest at the higher TEA level.
Example 4
Methylation of a mixture of 2′,4″-bisTMS-erythromycin A oxime IPCH ketal and 4″-TMS erythromycin A oxime IPCH ketal;
Reference methylation procedure with KOH base and no TEA
A solution of a mixture of 2′,4″-bisTMS-erythromycin A oxime IPCH ketal and 4″-TMS-erythromycin A oxime IPCH ketal (3.07 and 1.0 mmol, respectively) in 1:1 THF:DMSO (50 mL) was prepared. The solution was cooled to 0°5° C., and methyl bromide (0.85 g, 9.0 mmol) and KOH (0.47 g, 8.3 mmol) were added in that order. The reaction mixture was stirred for 30 minutes, then the reaction was diluted by addition of 100 mL of heptane, and 20 mL of 2N NaOH were added to quench the reaction. The layers were separated, and the organic layer was washed with water. The layers were separated, and a gummy by-product was collected. The heptane layer was dried over MgSO4, and the solvent was removed under vacuum to afford 2.95 g of product identified as the 6-O-methyl-2′,4″-bisTMS-erythromycin A oxime IPCH ketal (overall yield 69%). No methylated 4″-TMS product was obtained. The identity of the product was confirmed by comparison of its NMR spectrum with that of the reference product (see U.S. Pat. No. 4,990,602). The gummy by-product was dissolved in 25 mL of isopropyl acetate. The solution was dried and filtered, and the solvent removed under vacuum to give 0.91 g of a material identified as a quaternary salt by NMR spectroscopy. See Table 2 below for a summary of Examples 4, 5 and 6.
Example 5
Methylation of a mixture of 2′,4″-bisTMS-erythromycin A oxime IPCH ketal and 4″-TMS-erythromycin A oxime IPCH ketal:
Methylation procedure with KOH and low level of TEA
The procedure of Example 4 was followed, except that the order of addition of reagents to the solution of starting materials was TEA (1.0 g, 10.0 mmol), methyl bromide, then KOH, to afford 3.93 g of a mixture of desired products, 6-O-methyl-2′,4″-TMS-erythromycin A oxime IPCH ketal and 6-O-methyl-4″-TMS-erythromycin A oxime IPCH ketal (2.58 and 0.44 mmol, respectively; overall yield 74%). A modest amount of the quaternary by-product (0.41 g) was isolated. See Table 2 below for a summary of Examples 4, 5 and 6.
Example 6
Methylation of a mixture of 2′,4″-bisTMS-erythromycin A oxime IPCH ketal and 4″-TMS-erythromycin A oxime IPCH ketal;
Methylation procedure with KOH and high level of TEA
The procedure of Example 4 was followed, except that the order of addition of reagents to the solution of starting materials was TEA (3.5 g, 34.6 mmol), methyl bromide, then KOH, to afford 3.87 g of a mixture of desired products, 6-O-methyl-2′,4″-bisTMS-erythromycin A oxime IPCH ketal and 6-O-methyl-bisTMS-erythromycin A oxime IPCH ketal (2.48 and 0.72 mmol, respectively; overall yield 79%). A trace amount of the quaternary by-product was obtained. See Table 2 below for a summary of Examples 4, 5 and 6
TABLE 2
Summary of Example 4, 5 and 6.
starting material 6-O-methyl product com-
(mmol) (mmol) bined
Ex. 2′,4′- 4′-mono- 2′,4′-bis- 4′-mono- yield
No. Base bis-TMS TMS TMS TMS %
4 KOH 3.07 1.0 2.81 0 69
5 KOH + 3.07 1.0 2.58 0.45 74
low
TEA
6 KOH + 3.07 1.0 2.48 0.72 79
high
TEA
These data demonstrate that higher combined yields of product are obtained in the presence of TEA and that combined yields are highest at the higher TEA level.
Example 7
Methylation of mono-protected 4″-TMS-erythromycin A oxime IPCH ketal:
Methylation procedure with KOH only:
4″-TMS-erythromycin A oxime IPCH ketal (2.1 g 2.2 mmol) was dissolved in 1:1 THF:DMSO (25 mL). The solution was cooled to 0°-5° C., and methyl bromide (1.5 mL, 27 mmol) and KOH (0.2 g, 3.0 mmol) were added in that order. The reaction mixture was stirred for 1 hour, the reaction was diluted by addition of 50 mL of heptane, and 10 mL of 2N NaOH were added to quench the reaction. The layers were separated, a gummy by-product was collected, and the organic layer was washed with water. The heptane layer was dried over MgSO4, and the solvent was removed under vacuum. No product was observed. The gummy by-product was dissolved in 50 mL of isopropyl acetate. The solution was dried and filtered, and the solvent was removed under vacuum to give 1.5 g of a material identified as a quaternary ash by NMR spectroscopy. See Table 3 below for a summary of Examples 7 and 8.
Example 8
Methylation of mono-protected 4″-TMS-erythromycin A oxime IPCH ketal;
Methylation procedure with KOH and TEA:
The procedure of Example 7 was followed, except that the order of addition of reagents to the solution of starting material was TEA (3.5 g. 34.6 mmol), methyl bromide (0.5 mL, 9 mmol), then KOH (0.26 g, 3.9 mmol), to afford 1.32 g of the desired product, 6-O-methyl-4″-TMS-erythromycin A oxime IPCH keel (68% yield), and 0.32 g of the quaternary by-product. See Table 3 below for a summary of Examples 7 and 8.
TABLE 3
Summary of Examples 7 and 8.
starting material 6-O-methyl prod yield
Ex. No. Base (mmol) (g) (%)
7 KOH 2.2 0 0
8 KOH + high TEA 2.2 1.32 68
These data demonstrate 80 yield of 4′-mono-protected product is obtained without the presence of TEA.

!
Example 9
Methylation of mono-protected 2′-TMS-erythromycin A oxime IPCH ketal:
Methylation procedure with KOH only
2′-TMS-erythromycin A oxime IPCH ketal (2.1 g, 2.2 mmol) was dissolved in 1:1 THF:DMSO (25 mL). The solution was cooled to 0°-5° C., and methyl bromide (1.0 mL 2.8 mmol) and KOH (0.2 g, 3.0 mmol) were added in that order. The reaction mixture was stirred for 1 hour, the reaction was diluted by addition of 50 mL of heptane, and 10 mL of 2N NaOH were added to quench the reaction. The layers were separated, a gummy by-product was collected, and the organic layer was washed with water. The heptane layer was dried over MgSO4, and the solvent was removed under vacuum to afford 1.54 g of 6-O-methyl-2′-TMS-erythromycin A oxime IPCH ketal (69% yield). The gummy by-product was dissolved in 50 mL of isopropyl acetate. The solution was dried and filtered, and the solvent was removed under vacuum to give 0.36 g of a material identified as a quaternary salt by NMR spectroscopy. See Table 4 below for a summary of Examples 9 and 10.
Example 10
Methylation of mono-protected 2′-TMS-erythromycin A oxime IPCH ketal:
Methylation procedure with KOH and TEA
The procedure of Example 9 was followed, except that the order of addition of reagents to the solution of starting material was TEA (1.75 g, 17.3 mmol), methyl bromide (0.5 mL, 9.0 mmol), then KOH (0.23 g, 3.0 mmol), to afford 1.84 g of the desired product, 6-O-methyl-2′-TMS-erythromycin A oxime IPCH ketal (74.5% yield), and 0.1 g of the quaternary by-product. See Table 4 below for a summary of Examples 9 and 10.
TABLE 4
Summary of Examples 9 and 10.
starting material 6-O-methyl prod yield
Ex. No. Base (mmol) (g) (%)
9 KOH 2.2 1.54 69
10 KOH + TEA 2.2 1.84 74.5
These data demonstrate that higher yields of 2′-mono-protected product is obtained in the presence of TEA.

Claims (14)

1. An improved process for selective alkylation of a hydroxy group at the 6-position of a compound of the formula:
Figure USRE039383-20061107-C00010
wherein:
R1 and R2 are independently hydrogen or a hydroxy-protecting group, except that R1 and R2 may not both be hydrogen simultaneously;
Y is selected from the group consisting of
a) oxygen,
b) an oxime having the formula N-O-R3, wherein R3 is selected from the group consisting of
hydrogen,
a loweralkenyl group,
an aryl(loweralkyl) group, or
a substituted aryl(loweralkyl) group; and
c) to oxime having the formula:
Figure USRE039383-20061107-C00011
wherein
R4 is a loweralkyl group,
a cycloalkyl group;
a phenyl group,
an aryl(loweralkyl) group;
or R4 and R5 or R4 and R6 and the atoms to which they and attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
R5 is a loweralkyl group;
a loweralkoxymethyl group;
or R5 and R4 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom,
or R5 and R6 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group; and
R6 is a hydrogen atom,
a loweralkyl group,
a phenyl group,
an aryl(loweralkyl) group;
or R6 and R4 and the atoms to which they are attached are taken together form a 5- to 7-membered ring containing one oxygen atom;
or R6 and R5 and the atoms to which they are attached are taken together form a 5- to 7-membered cycloalkyl group;
with the requirement that only one pair of substituents (R4 and R5), (R4 and R6) or (R5 and R6) may be taken together with the atoms to which they are attached to form a ring as defined above; and
Z is hydrogen, hydroxy or protected-hydroxy;
comprising reacting the compound with an alkylating agent in the presence of both a strong alkali metal base and a weak organic amine base in polar aprotic solvent or a mixture of polar aprotic solvents maintained at a reaction temperature for a period of time sufficient to complete the alkylation, by adding the weak organic base prior to the addition of the alkylating agent and the strong alkali metal base.
2. The process according to claim 1, wherein the weak organic amine base is selected from the group consisting of trimethyl-amine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1-methyl-pyrrolidine, 1-methylpiperidine, and 1-ethylpiperidine.
3. The process according to claim 1, wherein the alkylating agent is selected from the group consisting of methyl bromide, methyl iodide, dimethyl sulfate and methyl-p-toluenesulfonate.
4. The process according to claim 1, wherein the solvent is a mixture of solvents selected from the group consisting of N,N-dimethyl-formamide, dimethyl sulfoxide, N-methyl-2-pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile and ethyl acetate.
5. The process according to claim 1, wherein R1 and R2 in the compound are independently hydrogen or a hydroxy-protecting group, which is benzyloxycarbonyl, acetyl, or a substituted silyl group of formula SiR7R8R9, wherein R7, R8 and a R9 are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms; with the provisions that at least one of R7, R8 and R9 is not a hydrogen atom.
6. The process according to claim 1, wherein the compound is 2′mono trimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal, or 4″ monotrimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal.
7. The process according to claim 1, wherein the compound is a mixture of 2′ mono trimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal and 4″ monotrimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal.
8. An improved process for preparing 6-O-methylerythromycin A comprising;
(a) reacting a compound of the formula
Figure USRE039383-20061107-C00012
wherein:
R 1 and R 2 are independently hydrogen or a hydroxy-protecting group, except that R 1 and R 2 may not both be hydrogen simultaneously; and
Y is selected from the group consisting of:
a) oxygen,
b) an oxime having the formula N-O-R 3 , wherein R 3 is selected from the group consisting of:
hydrogen,
a loweralkenyl group,
an aryl(loweralkyl) group, or
a substituted aryl(loweralkyl) group; and
c) an oxime having the formula:
Figure USRE039383-20061107-C00013
wherein
R 4 is
a loweralkyl group,
a cycloalkyl group,
a phenyl group,
an aryl(loweralkyl) group,
or R 4 and R 5 or R 4 and R 6 and the atoms to which they are attached are taken together form a 5 - to 7 -membered ring containing one oxygen atom;
R 5 is
a loweralkyl group,
a loweralkoxymethyl group,
or R 5 and R 4 and the atoms to which they are attached are taken together form a 5 - to 7 -membered ring containing one oxygen atom,
or R 5 and R 6 and the atoms to which they are attached are taken together form a 5 - to 7 -membered cycloalkyl group; and
R 6 is
a hydrogen atom,
a loweralkyl group,
a phenyl group,
an aryl(loweralkyl) group;
or R 6 and R 4 and the atoms to which they are attached are taken together form a 5 - to 7 -membered ring containing one oxygen atom,
or R 6 and R 5 and the atoms to which they are attached are taken together form a 5 - to 7 -membered cycloalkyl group;
 with the requirement that only one pair of substituents (R 4 and R 5), (R 4 and R 6) or (R 5 and R 6) may be taken together with the atoms to which they are attached to form a ring as defined above;
with a methylating agent in the presence of both a strong alkali metal base and a weak organic amine base in polar aprotic solvent or a mixture of polar aprotic solvents maintained at a reaction temperature for a period of time sufficient to complete the methylation, by adding the weak organic base prior to the addition of the methylating agent and the strong alkali metal base; and
(b) deprotecting at the 2′ and/or 4″ positions, and optionally deprotecting at the 9 position.
9. The process according to claim 8, wherein the weak organic amine base is selected from the group consisting of trimethylamine, triethylamine, tripropylamine, pyridine, 2-methoxypyridine, 1 -methyl-pyrrolidine, 1 -methylpiperidine, and 1 -ethylpiperidine.
10. The process according to claim 8, wherein the methylating agent is selected from the group consisting of methyl bromide, methyl iodide, dimethyl sulfate and methyl-p-toluenesulfonate.
11. The process according to claim 8, wherein the solvent is a mixture of solvents selected from the group consisting of N,N-dimethyl-formamide, dimethyl sulfoxide, N-methyl- 2 -pyrrolidone, hexamethylphosphoric triamide, tetrahydrofuran, 1,2 -dimethoxyethane, acetonitrile and ethyl acetate.
12. The process according to claim 8, wherein R1 and R 2 in the compound are independently hydrogen or a hydroxy-protecting-group, which is benzyloxycarbonyl, acetyl, or a substituted silyl group of formula SiR 7 R 8 R 9 , wherein R 7 , R 8 and R 9 are the same or different and each is a hydrogen atom, a loweralkyl group, a phenyl-substituted alkyl group in which the alkyl moiety has 1 to 3 carbon atoms, a phenyl group, a cycloalkyl group having 5 to 7 carbon atoms, or a loweralkenyl group having 2 to 5 carbon atoms; with the provision that at least one of R 7 , R 8 and R 9 is not a hydrogen atom.
13. The process according, to claim 8, wherein the compound is 2′ mono trimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal, or 4″monotrimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal.
14. The process according to claim 8, wherein the compound is a mixture of 2″ mono trimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal and 4″ monotrimethylsilyl erythromycin A oxime isopropyl cyclohexyl ketal.
US10/806,089 1995-11-21 2004-03-22 Process for 6-O-alkylation of erythromycin derivatives Expired - Lifetime USRE39383E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/806,089 USRE39383E1 (en) 1995-11-21 2004-03-22 Process for 6-O-alkylation of erythromycin derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/560,752 US5872229A (en) 1995-11-21 1995-11-21 Process for 6-O-alkylation of erythromycin derivatives
US10/806,089 USRE39383E1 (en) 1995-11-21 2004-03-22 Process for 6-O-alkylation of erythromycin derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/560,752 Reissue US5872229A (en) 1995-11-21 1995-11-21 Process for 6-O-alkylation of erythromycin derivatives

Publications (1)

Publication Number Publication Date
USRE39383E1 true USRE39383E1 (en) 2006-11-07

Family

ID=24239215

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/560,752 Ceased US5872229A (en) 1995-11-21 1995-11-21 Process for 6-O-alkylation of erythromycin derivatives
US10/806,089 Expired - Lifetime USRE39383E1 (en) 1995-11-21 2004-03-22 Process for 6-O-alkylation of erythromycin derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/560,752 Ceased US5872229A (en) 1995-11-21 1995-11-21 Process for 6-O-alkylation of erythromycin derivatives

Country Status (11)

Country Link
US (2) US5872229A (en)
EP (1) EP0874862B1 (en)
JP (2) JP2000500488A (en)
AT (1) ATE236919T1 (en)
CA (1) CA2237470C (en)
DE (1) DE69627381T2 (en)
DK (1) DK0874862T3 (en)
ES (1) ES2196184T3 (en)
MX (1) MX9804047A (en)
PT (1) PT874862E (en)
WO (1) WO1997019096A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
IL127833A (en) 1996-07-29 2004-06-20 Abbott Lab Preparation of crystal form ii of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5892008A (en) * 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100317907B1 (en) * 1998-11-24 2001-12-24 김 완 주 Novel Intermediates, process for preparing macrolide antibiotic agent therefrom
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
KR100336447B1 (en) * 1999-11-24 2002-05-15 민경윤 Improved method of preparing clarithromycin
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
CZ20021999A3 (en) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Process for preparing clarithromycin polymorphic forms and novel polymorph IV
PT1280535E (en) * 2000-01-11 2005-04-29 Teva Pharma PROCESSES FOR THE PREPARATION OF CLARITHROMYCINE POLYMORPHES
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU771825B2 (en) * 2000-03-15 2004-04-01 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
KR20000037126A (en) * 2000-04-08 2000-07-05 김용규 Process for preparing 6-methyl erythromycin A
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
TWI246515B (en) 2001-05-30 2006-01-01 Abbott Lab An arylation method for the functionalization of O-allyl erythromycin derivatives
US7435805B2 (en) 2003-05-30 2008-10-14 Glaxpsmithkline Istrazivacki O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007502296A (en) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869444A (en) 1972-10-10 1975-03-04 Abbott Lab Esters of erythromycin oxime
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4349545A (en) 1980-01-11 1982-09-14 Roussel Uclaf Novel erythromycin a derivatives
EP0063489A1 (en) 1981-04-20 1982-10-27 Pfizer Inc. 4"-Modified methylene oleandomycins
EP0080819A1 (en) 1981-11-30 1983-06-08 Taisho Pharmaceutical Co. Ltd 11-0-Alkylerythromycin A derivatives
US4476298A (en) 1981-12-03 1984-10-09 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US4496717A (en) 1981-12-01 1985-01-29 Taisho Pharmaceutical Co., Ltd. Erythromycin B derivatives
US4526889A (en) 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
EP0194833A2 (en) 1985-03-12 1986-09-17 Beecham Group Plc Erythromycin derivatives
EP0201166A1 (en) 1985-03-12 1986-11-12 Beecham Group Plc Erythromycin derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4668776A (en) 1985-04-03 1987-05-26 Nippon Zeon Co. Ltd. Protected des-N-methylerythromycin derivative
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives
US4680386A (en) 1984-10-26 1987-07-14 Taisho Pharmaceutical Co., Ltd. 6-O-methylerythromycin a derivative
EP0260938A2 (en) 1986-09-18 1988-03-23 Taisho Pharmaceutical Co. Ltd Erythromycin A derivatives and method for preparing the same
US4740502A (en) 1986-06-20 1988-04-26 Abbott Laboratories Semisynthetic erythromycin antibiotics
EP0272110A2 (en) 1986-12-17 1988-06-22 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for the preparation of the same
US4833236A (en) 1986-05-02 1989-05-23 Taisho Pharmaceutical Co., Ltd. Erythromycin derivatives
US5274085A (en) 1988-05-19 1993-12-28 Taisho Pharmaceutical Co., Ltd. Process for preparing erythromycin A oxime or a salt thereof
US5302705A (en) 1989-10-07 1994-04-12 Taisho Pharmaceutical Co., Ltd. 6-O-methylerythromycin a oxime derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120895A (en) * 1983-12-02 1985-06-28 Taisho Pharmaceut Co Ltd Process for producing 6-0-methyl-2'-0,N-bis(benzyloxycarbonyl)-N-demethylerythromycin A
JPH0764867B2 (en) * 1986-09-18 1995-07-12 大正製薬株式会社 6-O-methylerythromycin A derivative and method for producing the same
JP2526951B2 (en) * 1986-12-17 1996-08-21 大正製薬株式会社 Erythromycin A derivative and method for producing the same
JP2782793B2 (en) * 1988-06-15 1998-08-06 大正製薬株式会社 Erythromycin A derivative and method for producing the same

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869444A (en) 1972-10-10 1975-03-04 Abbott Lab Esters of erythromycin oxime
US4349545A (en) 1980-01-11 1982-09-14 Roussel Uclaf Novel erythromycin a derivatives
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
EP0063489A1 (en) 1981-04-20 1982-10-27 Pfizer Inc. 4"-Modified methylene oleandomycins
EP0080819A1 (en) 1981-11-30 1983-06-08 Taisho Pharmaceutical Co. Ltd 11-0-Alkylerythromycin A derivatives
US4496717A (en) 1981-12-01 1985-01-29 Taisho Pharmaceutical Co., Ltd. Erythromycin B derivatives
US4476298A (en) 1981-12-03 1984-10-09 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US4526889A (en) 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives
US4680386A (en) 1984-10-26 1987-07-14 Taisho Pharmaceutical Co., Ltd. 6-O-methylerythromycin a derivative
EP0194833A2 (en) 1985-03-12 1986-09-17 Beecham Group Plc Erythromycin derivatives
EP0201166A1 (en) 1985-03-12 1986-11-12 Beecham Group Plc Erythromycin derivatives
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4668776A (en) 1985-04-03 1987-05-26 Nippon Zeon Co. Ltd. Protected des-N-methylerythromycin derivative
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4833236A (en) 1986-05-02 1989-05-23 Taisho Pharmaceutical Co., Ltd. Erythromycin derivatives
US4740502A (en) 1986-06-20 1988-04-26 Abbott Laboratories Semisynthetic erythromycin antibiotics
EP0260938A2 (en) 1986-09-18 1988-03-23 Taisho Pharmaceutical Co. Ltd Erythromycin A derivatives and method for preparing the same
EP0272110A2 (en) 1986-12-17 1988-06-22 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for the preparation of the same
US4990602A (en) * 1986-12-17 1991-02-05 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US5274085A (en) 1988-05-19 1993-12-28 Taisho Pharmaceutical Co., Ltd. Process for preparing erythromycin A oxime or a salt thereof
US5302705A (en) 1989-10-07 1994-04-12 Taisho Pharmaceutical Co., Ltd. 6-O-methylerythromycin a oxime derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Judge David H. Coar, Opinion and Order on Motion for Preliminary Injunction, Abbott Labs v. Teva Pharms. USA, Inc., Case No. 1:05CV1490 (N.D. ILL. Jun. 3, 2005).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin

Also Published As

Publication number Publication date
JP2000500488A (en) 2000-01-18
WO1997019096A3 (en) 1997-07-03
EP0874862A2 (en) 1998-11-04
DK0874862T3 (en) 2003-07-28
ES2196184T3 (en) 2003-12-16
DE69627381T2 (en) 2004-03-25
CA2237470A1 (en) 1997-05-29
WO1997019096A2 (en) 1997-05-29
CA2237470C (en) 2005-01-18
JP2008110976A (en) 2008-05-15
PT874862E (en) 2003-08-29
EP0874862B1 (en) 2003-04-09
DE69627381D1 (en) 2003-05-15
MX9804047A (en) 1998-09-30
US5872229A (en) 1999-02-16
ATE236919T1 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
USRE39383E1 (en) Process for 6-O-alkylation of erythromycin derivatives
EP0966477B1 (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
EP1040107B1 (en) 6-o-alkyl derivatives of erythronolide b
EP0891370B1 (en) 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives
US5929219A (en) 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
EP2963048A1 (en) Method for producing -halo-tetraacyl glucose
KR20010032613A (en) Chemical synthesis of 6-O-alkyl erythromycin C
CA2250736C (en) 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives
MXPA00005402A (en) 6-o-alkyl derivatives of erythronolide b
MXPA99007519A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
MXPA00005404A (en) Chemical synthesis of 6-o-alkyl erythromycin c

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12

CC Certificate of correction
AS Assignment

Owner name: ABBVIE INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030155/0974

Effective date: 20120801